Fan X (2025) The mechanism of immunotherapy combined with chemotherapy. Created with BioRender.com. https://BioRender.com/nwnjr8c

Bray F, Laversanne M, Weiderpass E, Soerjomataram I (2021) The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 127(16):3029–3030

Article  PubMed  Google Scholar 

Kaur R, Bhardwaj A, Gupta S (2023) Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep 50(11):9663–9676

Article  PubMed  Google Scholar 

DeVita VT Jr., Chu E (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643–8653

Article  PubMed  Google Scholar 

Wockel A, Albert US, Janni W, Scharl A, Kreienberg R, Stuber T (2018) The screening, diagnosis, treatment, and follow-up of breast cancer. Dtsch Arztebl Int 115(18):316–323

PubMed  PubMed Central  Google Scholar 

Jaaback K, Johnson N, Lawrie (2016)TA Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2016(1):CD005340

Goldkuhle M, Kreuzberger N, von Tresckow B, Eichenauer DA, Specht L, Monsef I, Skoetz N (2024) Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage hodgkin’s lymphoma. Cochrane Database Syst Rev 12(12):CD007110

PubMed  PubMed Central  Google Scholar 

Pardoll DM (2012) The Blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264

Article  PubMed  PubMed Central  Google Scholar 

Livingstone A, Agarwal A, Stockler MR, Menzies AM, Howard K, Morton RL (2020) Preferences for immunotherapy in melanoma: a systematic review. Ann Surg Oncol 27(2):571–584

Article  PubMed  Google Scholar 

Dogan V, Rieckmann T, Munscher A, Busch CJ (2018) Current studies of immunotherapy in head and neck cancer. Clin Otolaryngol 43(1):13–21

Article  PubMed  Google Scholar 

Li J, Xuan S, Dong P, Xiang Z, Gao C, Li M, Huang L, Wu J (2023) Immunotherapy of hepatocellular carcinoma: recent progress and new strategy. Front Immunol 14:1192506

Article  PubMed  PubMed Central  Google Scholar 

Peinemann F, Unverzagt S, Hadjinicolaou AV, Moldenhauer I (2019) Immunotherapy for metastatic renal cell carcinoma: a systematic review. J Evid Based Med 12(4):253–262

Article  PubMed  Google Scholar 

Pusuluri A, Wu D, Mitragotri S (2019) Immunological consequences of chemotherapy: single drugs, combination therapies and nanoparticle-based treatments. J Control Release 305:130–154

Article  PubMed  Google Scholar 

Xue J, Yan X, Ding Q, Li N, Wu M, Song J (2023) Effect of neoadjuvant chemotherapy on the immune microenvironment of gynaecological tumours. Ann Med 55(2):2282181

Article  PubMed  PubMed Central  Google Scholar 

Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, Albelda SM (2010) Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 18(11):1947–1959

Article  PubMed  PubMed Central  Google Scholar 

He X, Lan H, Jin K, Liu F (2023) Can immunotherapy reinforce chemotherapy efficacy? A new perspective on colorectal cancer treatment. Front Immunol 14:1237764

Article  PubMed  PubMed Central  Google Scholar 

Karati D, Mahadik KR, Trivedi P, Kumar D (2022) Alkylating agents, the road less traversed, changing anticancer therapy. Anticancer Agents Med Chem 22(8):1478–1495

Article  PubMed  Google Scholar 

Ghosh S (2019) Cisplatin: the first metal based anticancer drug. Bioorg Chem 88:102925

Article  PubMed  Google Scholar 

Maksimovic V, Pavlovic-Popovic Z, Vukmirovic S, Cvejic J, Mooranian A, Al-Salami H, Mikov M, Golocorbin-Kon S (2020) Molecular mechanism of action and Pharmacokinetic properties of methotrexate. Mol Biol Rep 47(6):4699–4708

Article  PubMed  Google Scholar 

Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD (2014) Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol 11(5):282–298

Article  PubMed  Google Scholar 

Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253–265

Article  PubMed  Google Scholar 

Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H (1990) Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47(2):219–231

Article  PubMed  Google Scholar 

Emens LA, Middleton G (2015) The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 3(5):436–443

Article  PubMed  PubMed Central  Google Scholar 

Garg AD, Martin S, Golab J, Agostinis P (2014) Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 21(1):26–38

Article  PubMed  Google Scholar 

Li Z, Lai X, Fu S, Ren L, Cai H, Zhang H, Gu Z, Ma X, Luo K (2022) Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv Sci 9(22):e2201734

Article  Google Scholar 

Zhang X, Wang D, Li Z, Jiao D, Jin L, Cong J, Zheng X, Xu L (2020) Low-dose gemcitabine treatment enhances immunogenicity and natural killer cell-driven tumor immunity in lung cancer. Front Immunol 11:331

Article  PubMed  PubMed Central  Google Scholar 

Hayashi K, Nikolos F, Lee YC, Jain A, Tsouko E, Gao H, Kasabyan A, Leung HE, Osipov A, Jung SY et al (2020) Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nat Commun 11(1):6299

Article  PubMed  PubMed Central  Google Scholar 

Park SJ, Ye W, Xiao R, Silvin C, Padget M, Hodge JW, Van Waes C, Schmitt NC (2019) Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Oral Oncol 95:127–135

Article  PubMed  PubMed Central  Google Scholar 

Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L et al (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29(4):482–491

Article  PubMed  Google Scholar 

Kaneno R, Shurin GV, Kaneno FM, Naiditch H, Luo J, Shurin MR (2011) Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol (Dordr) 34(2):97–106

Article  PubMed  Google Scholar 

Rivera Vargas T, Apetoh L (2017) Danger signals: chemotherapy enhancers? Immunol Rev 280(1):175–193

Article  PubMed  Google Scholar 

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050–1059

Article  PubMed  Google Scholar 

Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54–61

Article  PubMed  Google Scholar 

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15(10):1170–1178

Article  PubMed  Google Scholar 

Joffre O, Nolte MA, Sporri R, Reis e Sousa C (2009) Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 227(1):234–247

Article  PubMed  Google Scholar 

Kalinski P, Muthuswamy R, Urban J (2013) Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines 12(3):285–295

Article  PubMed  PubMed Central